The board of directors of Simcere Pharmaceutical Group Limited announced that, on March 15, 2024, the New Drug Application of Suvemcitug for injection has been accepted by the National Medical Products Administration of China ("NMPA"). The indication is Suvemcitug combined with chemotherapy for the treatment of recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. Suvemcitug is a new-generation recombinant humanized anti-VEGF rabbit monoclonal antibody developed by the Group and Apexigen Inc. Pre-clinical studies have shown that Suvemcitug has higher affinity and anti-tumor efficacy than Bevacizumab at the same dose in multiple tumor models.

The phase Ib clinical studies of Suvemcitug conducted in China for the treatment of ovarian cancer preliminary demonstrated its favorable safety profile and efficacy signals. On January 3, 2024, the phase III clinical trial of Suvemcitug for injection combined with chemotherapy versus placebo combined with chemotherapy in patients with recurrent, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (the SCORES study) met the primary endpoint. On March 11, 2024, the Group submitted the New Drug Application of Suvemcitug for injection to the NMPA.